Navigation Links
GNC Unveils Study Results for First and Only Nitric Oxide Product Clinically Proven to Improve Physical Performance at NSCA Conference in Las Vegas
Date:7/13/2009

LAS VEGAS, July 13 /PRNewswire-FirstCall/ -- GNC, the leading global specialty retailer of nutritional products, announced today clinical results for the first and only nitric oxide product, Amplified Maxertion N.O., proven to demonstrate a delay in the onset of neuromuscular fatigue. The key findings were unveiled at the National Strength and Conditioning Association (NSCA) conference in Las Vegas, NV.

GNC's Amplified Maxertion N.O.(TM) was shown to increase power output at the onset of neuromuscular fatigue by an average of 20% and improve physical performance by helping athletes push past their normal point of exhaustion. This product is designed to increase nitric oxide levels in the body causing a hemodilation effect which expands blood vessels, allowing more blood, oxygen and nutrients to flow to muscles.

"This is truly groundbreaking research that has resulted in the delivery of a truly novel and clinically-validated product to the industry," said Guru Ramanathan, SVP Technology and Product Innovation for GNC. "Using advanced technology and ingredients, this is the first Nitric Oxide enhancing product to demonstrate significant athletic performance effects that are relevant and meaningful to all types of athletes."

The purpose of the double-blind placebo-controlled study was to examine the effects of daily administration of arginine-based supplements on the physical working capacity at the fatigue threshold (PWC(FT)). The PWC(FT) test estimates the highest power output that can be maintained without neuromuscular evidence of fatigue.

Using a cycle ergometer (stationary bicycle), all subjects performed an incremental test to exhaustion prior to supplementation and after four weeks of supplementation. Key study findings demonstrate significant mean increases in PWC(FT) for the 1.5 gm (22.4%) and 3.0 gm (18.8%) supplement groups, but no change for the placebo group (-1.6%).

The study followed 50 college-aged males over the course of four weeks who were randomized into one of three groups - a. placebo (microcrystalline cellulose), b. 1.5 gm of micronized arginine and 300 mg of grape seed extract, and c. 3.0 gm of micronized arginine and 300 mg of grape seed extract.

Amplified Maxertion N.O. is part of a comprehensive line of eight new advanced muscle performance and sports nutrition products from GNC. The entire Pro Performance(R) AMP line was developed through rigorous clinical research and is designed to suit the needs of a wide range of dedicated athletes, from the weekend warrior to the ultra competitive athlete.

About GNC

GNC, headquartered in Pittsburgh, Pa., is the largest global specialty retailer of nutritional products including vitamin, mineral, herbal and other specialty supplements and sports nutrition, diet and energy products. As of March 31, 2009, GNC has more than 5,200 retail locations throughout the United States (including 944 franchise and 1,733 Rite Aid store-within-a-store locations) and franchise operations in 44 international markets. The company -- which is dedicated to helping consumers Live Well -- also offers products and product information online at www.gnc.com.


'/>"/>
SOURCE GNC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oregon Tourism Commission Unveils New Online Customer Service Training Program
2. NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting
3. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
4. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
5. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
6. Boehringer Ingelheim Unveils Diabetes Pipeline
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a ... cells and other difficult to transfect cells, announces its launch of the PluriQ™ ... Gene Editing System is a complete system for culturing and transfecting human ...
Breaking Medicine News(10 mins):